Biological marker detection platform Alamar Biosciences (ALMR.US) applies for listing in the US, aims to raise $100 million.

Alamar Biosciences, which provides a protein biomarker detection platform for disease detection research, submitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) last Friday, aiming to raise up to $100 million. The company plans to list on Nasdaq under the ticker symbol "ALMR". Founded in 2018, Alamar Biosciences is headquartered in Fremont, California. The company focuses on developing and commercializing proteomics technology to detect and analyze very low concentrations of protein biomarkers in biological samples such as blood. Its platform integrates its own instruments, consumables, and software, providing an end-to-end system for measuring various low-abundance proteins in research and potential clinical applications. The company's technology is applied in multiple areas from early discovery to translational research, with a focus on achieving more precise and consistent protein detection. Data shows that the company generated $74 million in revenue in the 12 months ending on December 31, 2025.